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To the Editor:
The myelodysplastic syndromes (MDS) are common mye-
loid malignancies characterized by ineffective hematopoi-
esis and blood cytopenias, with patients showing increasing
bone marrow blasts with disease progression [1]. Mutations
in genes involved in pre-mRNA splicing (SF3B1, SRSF2,
U2AF1, and ZRSR2) are the most common mutations found
in MDS, occurring in over 50% of all cases [2–4]. There is
evidence that some spliceosome components play a role in
the maintenance of genomic stability [5]. Splicing is a
transcription coupled process; splicing factor mutations
affect transcription and may lead to the accumulation of R-
loops (RNA-DNA hybrids with a displaced single stranded
DNA) [6]. Mutations in the splicing factors SRSF2 and
U2AF1 have been recently shown to increase R-loop for-
mation in leukemia cell lines, resulting in increased DNA
damage, replication stress, and activation of the ATR-Chk1
pathway [7, 8]. SF3B1 is the most frequently mutated
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splicing factor gene in MDS, with mutations occurring
in 25–30% of MDS patients [9–11]. SF3B1 mutations are
also found at lower frequency in other hematological
malignancies [4, 11] and in some individuals with clonal
hematopoiesis of indeterminate potential [12]. A role of
SF3B1 mutations in R-loop accumulation and DNA damage
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has not yet been reported in hematopoietic cells. Here, we
investigated the effects of SF3B1 mutations on R-loop
formation and associated DNA damage response in MDS
and leukemia cells, and we also explored potential ther-
apeutic implications.
Firstly, we investigated the effects of SF3B1 mutations
on the formation of R-loops, as measured by immuno-
fluorescence staining using the S9.6 antibody (Supplemen-
tary Materials and Methods) [7]. K562 cells (a myeloid
leukemia cell line) with the SF3B1K700E mutation showed a
significant increase in the number of S9.6 foci, indicating
increased R-loops, compared with isogenic SF3B1K700K
K562 cells (Fig. 1a, S1A). We then analyzed induced
pluripotent stem cells (iPSCs) that we generated (and
characterized, Fig. S2) from bone marrow CD34+ cells of
one SF3B1 mutant MDS patient and of one healthy control
(Supplementary Materials and Methods). A significant
increase in R-loops was observed in an iPSC clone har-
boring the SF3B1 mutation compared with another iPSC
clone without the SF3B1 mutation obtained from same
MDS patient, and to iPSCs from the healthy control
(Fig. 1b). We have also analyzed the levels of R-loops in the
bone marrow CD34+ cells from three SF3B1 mutant MDS
patients, three splicing factor wildtype MDS patients, and
three healthy controls. Importantly, CD34+ cells from
SF3B1 mutant MDS patients (Table S1) showed a sig-
nificant and marked increase in R-loops compared with
CD34+ cells from MDS patients without splicing factor
mutations (2.4-fold) and from healthy controls (2.6-fold)
(Fig. 1c, S1B). Our results demonstrate that an accumula-
tion of R-loops occurs in association with the presence of
SF3B1 mutations in MDS and leukemia cells.
We then investigated the effects of SF3B1mutations on the
DNA damage response, as measured by immunofluorescence
staining using anti-γ-H2AX antibody (Supplementary Mate-
rials and Methods) [7]. K562 cells with the SF3B1K700E
mutation showed a significant increase in the number of γ-
H2AX foci, indicating increased DNA damage, compared
with isogenic control SF3B1K700K K562 cells (Fig. 1d, S3A).
Similarly, an iPSC clone harboring the SF3B1 mutation
showed increased DNA damage as compared with another
iPSC clone without the SF3B1 mutation obtained from same
MDS patient and to iPSCs from a healthy control (Fig. 1e).
Bone marrow CD34+ cells from SF3B1 mutant MDS
patients showed significantly increased DNA damage com-
pared with CD34+ cells from MDS patients without splicing
factor mutations and from healthy controls (Fig. 1f, S3B).
To investigate whether the observed DNA damage in
SF3B1 mutant K562 cells results from induced R-loops, we
overexpressed RNaseH1 (encoding an enzyme that
degrades the RNA in RNA:DNA hybrids) to resolve R-
loops in these cells. RNaseH1 overexpression significantly
reduced the number of S9.6 foci in SF3B1K700E K562 cells
compared with SF3B1K700E K562 cells expressing an empty
vector (Fig. 1g, h). Furthermore, SF3B1K700E K562 cells
expressing WKKD mutant RNaseH1 (lacking hybrid
binding and RNaseH1 activity) did not show a decrease in
the number of S9.6 foci (Fig. 1g, h). RNaseH1 over-
expression also significantly reduced the number of γ-
H2AX foci (Fig. 1i, j) in SF3B1K700E K562 cells compared
with SF3B1K700E K562 cells expressing an empty vector.
Further, western blot analysis of γ-H2AX levels in
SF3B1K700E K562 cells expressing RNaseH1 also showed
decreased levels of γ-H2AX (Fig. S4). These data demon-
strate that increased levels of R-loops result in increased
DNA damage in SF3B1 mutant leukemia cells.
Next, to investigate the signaling events related to DNA
damage in SF3B1 mutant cells, we have studied ATR and
ATM signaling, two pathways that are frequently activated
following DNA damage [13]. The ATR signaling pathway
was analyzed by measuring the levels of Chk1 phosphor-
ylation at Ser345, a hallmark of activation of the ATR
pathway, in K562 cells (Supplementary Materials and
Methods). We observed increased phosphorylation of Chk1
in K562 cells with the SF3B1K700E mutation compared with
isogenic SF3B1K700K K562 cells (Fig. S5A). Suppression of
R-loops by RNaseH1 overexpression resulted in decreased
Chk1 phosphorylation, indicating suppression of ATR
pathway activation in SF3B1K700E K562 cells (Fig. S5A). In
contrast, we did not observe activation of the ATM
Fig. 1 SF3B1 mutation leads to increased R-loops and associated
DNA damage response. Quantitative analysis of S9.6 foci detected by
immunocytochemistry in (a) SF3B1K700K and SF3B1K700E K562 cells
(n > 300 cells/category) (b) iPSC clones generated from an MDS
patient sample with SF3B1 mutation (MDS SF3B1Mut: iPSC clone
harboring the SF3B1mutation; MDS SF3B1WT: iPSC clone without the
SF3B1 mutation) and from a healthy control (n > 150 cells/category) (c)
CD34+ cells from MDS patients with SF3B1 mutation (MDS
SF3B1Mut), from MDS patients without splicing factor mutations (MDS
SFWT), and from healthy controls (n > 300 cells/category). Quantitative
analysis of γ-H2AX foci detected by immunocytochemistry in (d)
SF3B1K700K and SF3B1K700E K562 cells (n > 300 cells/category) (e)
iPSC clones generated from an MDS patient sample with SF3B1
mutation (MDS SF3B1Mut: iPSC clone harboring the SF3B1 mutation;
MDS SF3B1WT: iPSC clone without the SF3B1 mutation) and from a
healthy control (n > 100 cells/category) (f) CD34+ cells from MDS
patients with SF3B1 mutation (MDS SF3B1Mut), from MDS patients
without splicing factor mutations (MDS SFWT), and from healthy
controls (n > 150 cells/category). g Quantitative data and h repre-
sentative images of S9.6 foci detected by immunocytochemistry
in SF3B1K700K-EV, SF3B1K700E-EV, SF3B1K700E-RNaseH-WT, and
SF3B1K700E-RNaseH-WKKD K562 cells (n > 300 cells/category). Green-
S9.6; blue- DAPI. i Quantitative analysis and j representative images
of γ-H2AX foci in SF3B1K700K-EV, SF3B1K700E-EV, and
SF3B1K700E-RNaseH-WT K562 cells (n > 150 cells/category). Red- γ-
H2AX; blue: DAPI. All values are plotted as mean ± SEM. P values in
a and d were obtained using the unpaired Student’s T test. P values in
b–c, e–g, i were obtained using one-way ANOVA with the Tukey’s
multiple comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001. Scale bar −10 µm.
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signaling pathway in the SF3B1K700E K562 cells as ana-
lyzed by measuring the levels of ATM phosphorylation at
Ser1981, Chk2 phosphorylation at Thr68, and RPA32
phosphorylation at Ser4/8 (Fig. S5B). These data demon-
strate that SF3B1 mutations are associated with downstream
activation of ATR but not ATM signaling.
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We sought to explore the functional importance of ATR
activation associated with SF3B1 mutation and determine
whether this could represent a therapeutic vulnerability. We
evaluated the sensitivity of SF3B1 mutant cells to VE-821
(Supplementary Materials and Methods). SF3B1K700E K562
cells showed preferential sensitivity to the ATR inhibitor
VE-821 compared with isogenic SF3B1K700K K562 cells
(Fig. S6A). Chk1 is a critical substrate of ATR, and we next
chose to investigate the effects of Chk1 inhibition in
SF3B1K700E K562 cells. Interestingly, SF3B1K700E K562
cells demonstrated preferential sensitivity to the Chk1
inhibitor UCN-01 compared with SF3B1K700K K562 cells,
suggesting that ATR-Chk1 activation is important for the
survival of SF3B1 mutant cells (Fig. 2a). The effect of
RNaseH1 overexpression on the sensitivity of SF3B1K700E
K562 cells towards UCN-01 was also examined. We found
that the sensitivity of SF3B1K700E K562 towards UCN-01
decreased after overexpressing RNaseH1 (Fig. S6B).
Treatment with an ATM inhibitor (KU-55933) did not show
a significant difference in the sensitivity of SF3B1K700E
K562 cells compared with isogenic SF3B1K700K K562 cells
(Fig. S6C). Notably, bone marrow CD34+ cells from
SF3B1 mutant MDS patients showed preferential sensitivity
towards UCN-01 (Fig. 2b) and VE-821 (Fig. 2c) compared
with CD34+ cells from MDS patients without splicing
factor mutations and from healthy controls. These results
show that activation of ATR, but not ATM, plays an
important role for the survival of SF3B1 mutant cells, and
that these cells are vulnerable to Chk1 inhibition.
Preferential sensitivity of splicing factor mutant cells
towards splicing modulators has been reported previously
[4, 14, 15]. Thus, we investigated whether a splicing
modulator could increase the sensitivity of SF3B1 mutant
cells to ATR or Chk1 inhibition. The splicing modulator
Sudemycin D6 has been shown to preferentially kill U2AF1
mutant cells [14], but its effects on myeloid leukemia cells
with the SF3B1 mutation have not been evaluated. Here, we
showed that SF3B1K700E K562 cells were preferentially
sensitive to Sudemycin D6 compared with isogenic
SF3B1K700K K562 cells (Fig. 2d). Bone marrow CD34+
cells from SF3B1 mutant MDS patients showed preferential
sensitivity to Sudemycin D6 compared with CD34+ cells
from MDS patients without splicing factor mutations and
from healthy controls (Fig. 2e). We then tested the effects of
Sudemycin D6 in combination with an ATR inhibitor or a
Chk1 inhibitor. The effects of VE-821 and UCN-01 on
SF3B1 mutant K562 cells were enhanced by Sudemycin D6
(Fig. 2f, g). We have also determined the synergy scores of
Sudemycin D6 and UCN-01 (Fig. S7A, B), and Sudemycin
D6 and VE-821 (Fig. S7C, D) on SF3B1K700K and
SF3B1K700E K562 cells. Various dose combinations showed a
positive synergy score (δ-score), indicating synergy of
Sudemycin D6 with VE-821 and UCN-01, with higher
scores for SF3B1K700E K562 cells. Importantly, bone marrow
CD34+ cells from SF3B1 mutant MDS patients also showed
preferential sensitivity towards the combination of Sudemycin
D6 with UCN-01 (Fig. 2h) or with VE-821 (Fig. 2i).
In summary, we show for the first time that mutations of
SF3B1, the most commonly mutated splicing factor gene in
MDS [2, 3, 9, 11], lead to the accumulation of R-loops and
associated DNA damage, resulting in activation of the ATR
pathway in MDS and leukemia cells. The suppression of R-
loops rescued cellular defects including DNA damage and
ATR-Chk1 activation. Our current study on mutant SF3B1,
and previous studies by others on mutant U2AF1 and
SRSF2 [7, 8], together demonstrate that different mutated
splicing factors in hematopoietic cells all have convergent
effects on R-loop elevation leading to DNA damage. It is
possible that this R-loop induced DNA damage may give
rise to deleterious mutations in MDS hematopoietic stem
and progenitor cells, contributing to the clonal advantage of
splicing factor mutant cells in human bone marrow. Future
studies seeking to compare R-loop levels in the CD34+
cells of SF3B1 mutant MDS cases with those in CD34+
cells of MDS patients with mutations of other splicing
factors (SRSF2, U2AF1, ZRSR2) are warranted.
This is the first study showing that splicing factor mutant
MDS and leukemia cells are preferentially sensitive to the
Chk1 inhibitor UCN-01, suggesting that Chk1 inhibition,
alone or in combination with splicing modulators, may
represent a novel therapeutic strategy to target splicing
factor mutant cells. This strategy could also be potentially
extended to therapeutically target other types of cancers
known to harbor SF3B1 mutations. This study provides
preclinical evidence that MDS patients with spliceosome
Fig. 2 SF3B1 mutant cells are preferentially sensitive to UCN-01,
VE-821, and Sudemycin D6 and the effects of UCN-01 and VE-821
were synergistically enhanced by Sudemycin D6. a Viability of
SF3B1K700K and SF3B1K700E K562 cells treated with UCN-01. IC50
obtained for SF3B1K700K and SF3B1K700E K562 cells are 260.8 ±
1.05 nM and 61.53 ± 1.1 nM, respectively (n= 3). Effect of (b) UCN-
01 and (c) VE-821 treatment on viability of CD34+ cells from MDS
SF3B1Mut (n= 4), from MDS SFWT (n= 3), and from healthy controls
(n= 4). d Viability of SF3B1K700K and SF3B1K700E K562 cells treated
with the splicing modulator Sudemycin D6. IC50 obtained for
SF3B1K700K and SF3B1K700E K562 cells are 87.8 ± 1.09 nM and
41.1 ± 1.15 nM, respectively (n= 3). e Effect of Sudemycin D6 on
viability of CD34+ cells from MDS SF3B1Mut (n= 4), from MDS
SFWT (n= 3), and from healthy control (n= 4). Effect of combination
of different doses of (f) Sudemycin D6 and UCN-01 (n= 2) and (g)
Sudemycin D6 and VE-821 (n= 2) on viability of SF3B1K700K and
SF3B1K700E K562 cells. Effect of combination of (h) Sudemycin D6
(35 nM) and UCN-01 (35 nM) and (i) Sudemycin D6 (35 nM) and VE-
821 (5 µM) on viability of CD34+ cells from MDS SF3B1Mut (n= 3),
from MDS SFWT (n= 2), and from healthy controls (n= 3). All values
are plotted as mean ± SEM. Results shown in a and d were analyzed
by using nonlinear regression. P values for b–c, e, h–i are calculated
using one-way ANOVA with the Tukey’s multiple comparisons test.
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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mutations may benefit from Chk1 inhibition to exploit the
R-loop-associated vulnerability induced by these mutations.
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